Publicacions en col·laboració amb investigadors/es de Seoul St. Mary's Hospital (3)

2018

  1. Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study

    Leukemia, Vol. 32, Núm. 8, pp. 1799-1803

2017

  1. Health-related quality of life data from a phase 3, international, randomized, open-label, multicenter study in patients with previously treated mantle cell lymphoma treated with ibrutinib versus temsirolimus

    Leukemia and Lymphoma, Vol. 58, Núm. 12, pp. 2824-2832

2016

  1. Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: An international, randomised, open-label, phase 3 study

    The Lancet, Vol. 387, Núm. 10020, pp. 770-778